Home

Coherus Oncology, Inc. - Common Stock (CHRS)

1.4900
-0.0800 (-5.10%)
NASDAQ · Last Trade: Nov 7th, 2:48 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1.570
Open1.540
Bid1.430
Ask1.460
Day's Range1.420 - 1.600
52 Week Range0.6950 - 2.430
Volume2,012,197
Market Cap173.19M
PE Ratio (TTM)0.9371
EPS (TTM)1.6
Dividend & YieldN/A (N/A)
1 Month Average Volume1,067,736

Chart

About Coherus Oncology, Inc. - Common Stock (CHRS)

Coherus Bio is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions in the field of immunology and oncology. The company specializes in creating high-quality biologics, including biosimilars—products that are similar to already approved biological medicines. With a commitment to advancing patient care, Coherus Bio engages in research and clinical development to address unmet medical needs, aiming to make healthcare more accessible and affordable through its cutting-edge therapies. Read More

News & Press Releases

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer –
By Coherus Oncology, Inc. · Via GlobeNewswire · November 6, 2025
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
– Responsible for Corporate Development, Investor Relations, Government Affairs –
By Coherus Oncology, Inc. · Via GlobeNewswire · November 6, 2025
Earnings Scheduled For November 6, 2025benzinga.com
Via Benzinga · November 6, 2025
Coherus BioSciences's Earnings Outlookbenzinga.com
Via Benzinga · November 5, 2025
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus Oncology, Inc. · Via GlobeNewswire · October 30, 2025
Earnings Scheduled For August 7, 2025benzinga.com
Via Benzinga · August 7, 2025
Insights Ahead: Coherus BioSciences's Quarterly Earningsbenzinga.com
Via Benzinga · August 6, 2025
Coherus Oncology to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences:
By Coherus Oncology, Inc. · Via GlobeNewswire · October 23, 2025
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicalsbenzinga.com
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
Via Benzinga · October 10, 2025
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –
By Coherus Oncology, Inc. · Via GlobeNewswire · October 3, 2025
Earnings Scheduled For May 12, 2025benzinga.com
Via Benzinga · May 12, 2025
Earnings Preview: Coherus BioSciencesbenzinga.com
Via Benzinga · May 9, 2025
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursdaybenzinga.com
Via Benzinga · September 4, 2025
Coherus Oncology to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences:
By Coherus Oncology, Inc. · Via GlobeNewswire · September 3, 2025
Coherus (CHRS) Q2 Revenue Jumps 10%fool.com
Via The Motley Fool · August 7, 2025
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –
By Coherus Oncology, Inc. · Via GlobeNewswire · August 7, 2025
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus Oncology, Inc. · Via GlobeNewswire · July 31, 2025
Which stocks are moving after the closing bell on Friday?chartmill.com
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · July 4, 2025
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · July 3, 2025
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 27, 2025
Top movers in Friday's after hours sessionchartmill.com
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · May 23, 2025
Which stocks are moving before the opening bell on Tuesday?chartmill.com
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · May 13, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 13, 2025
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
– Strategic transformation to innovative oncology completed in Q2 2025 –
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 12, 2025
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 5, 2025